From April 11 to April 14, the fourth International specialized exhibition-forum Healthcare of the Urals – 2023 was held at the Ekaterinburg-Expo IEC, where the Medsintez Plant traditionally presented its products at the booth. The focus this year was on equipping the medical system in the regions of Russia. The focus on import independence in the current conditions also remains one of the key ones. 160 manufacturers and suppliers of medical products from 30 cities of Russia, which presented over a thousand pieces of various equipment, took part in the event.
The opening ceremony was attended by Aleksey Shmykov, First Deputy Governor of the Sverdlovsk Region, Alla Samoilova, Head of the Federal Service for Surveillance in Healthcare (Roszdravnadzor), and Boris Kirillov, Deputy Plenipotentiary Representative of the President of the Russian Federation in the Urals Federal District. On behalf of the head of the region, Evgeny Kuyvashev, First Deputy Governor Aleksey Shmykov delivered a welcoming speech.
“This is already the fourth exhibition-forum dedicated to the most important aspects of healthcare development. It originated here and has become traditional. I am very pleased that so many well-known specialists, prominent scientists, experts, and healthcare leaders are participating in it. I am sure that the interest in this event will grow every year, and the results of the industry specific exhibition will be another step in the development of our medicine, improving its quality and accessibility,” Aleksey Shmykov noted.
The head of Roszdravnadzor Alla Samoilova said she was confident that the exhibition would provide an opportunity for direct interaction between medical manufacturers and real consumers.
“Every year we can see more and more Russian-made goods at this exhibition. It's great! This suggests that our industry is developing, and our health care institutions do not lack equipment and can now be fully equipped with Russian equipment. I am sure that today’s exhibition will give birth to new ideas, new production capacities,” Alla Samoilova said.
The Medsintez Plant, a modern full-cycle biotechnological enterprise, has been present on the Russian market for over 20 years and ensures import-independence of our country regarding vital preparations. The booth of the plant presented own biotechnological drugs – genetically engineered human insulin of the Rosinsulin line, analogue insulins Rosinsulin Aspart R and Rosinsulin Glargine from own substances, and the first Russian drug of recombinant human follicle-stimulating hormone for the treatment of infertility Primapur. At the booth, one could also see a wide range of infusion solutions and the development of Ural scientists that we are proud of - the antiviral preparation Triazavirin.
An important event in 2023 for the Medsintez Plant was the registration of own analogue human insulin Rosinsulin Glargine (100 IU/ml). Thus, the Medsintez Plant has launched the production of a full cycle of the entire line of products of genetically engineered human insulin Rosinsulin and analogue insulins – Rosinsulin Aspart R and Rosinsulin Glargine from its own substances. An analogue medicine Rosinsulin Glargine 300 Medsintez with a concentration of 300 IU/ml has also been developed. Rosinsulin is produced in the most convenient and familiar dosage forms for consumers – in vials, cartridges and injection pens. The Medsintez Plant has developed and patented the design of disposable and reusable injection pens that ensure high precision dosing of the preparation. The insulin preparations production capacity makes it possible to meet 100% of the Russian market demand. In 2023, the Plant is preparing to release the first Russian insulins for veterinary use.
Over 10,000 children have already been born in Russia due to treating female patients using Primapur, the first Russian FSH preparation for infertility treatment that the Medsintez Plant has been producing since 2019. The preparation is completely Russian-made, is used in the treatment of infertility through in vitro fertilisation (IVF), and is included in List of Vital and Essential Drugs. The Medsintez Plant is ready to meet the annual demand for FSH preparations in Russia by 200%. The medicine is used in over 80% of medical centers specialized in the treatment of human infertility throughout Russia. Over 30,000 women have already been treated using this medicine. Today, the Medsintez Plant, together with the Ural State Medical University (USMU), is developing other preparations used in IVF procedure, which fact will allow creating a full cycle of these preparations and securing Russia from the lack of these preparations.
The Plant can provide substantial support to the country during epidemics or pandemics of diseases caused by RNA viruses. Since 2014, the Medsintez Plant produces the substance and the finished dosage form of Triazavirin, an original Russian preparation with proven direct antiviral activity against a wide range of RNA viruses. The preparation is effective for the treatment and prevention of viral diseases such as influenza, ARVI, COVID-19, tick-borne encephalitis, haemorrhagic fevers and others. Triazavirin is included in the federal clinical recommendations Influenza in Adults and ARVI in Adults of the Ministry of Health of Russia as a direct antiviral preparation. The drug has already proven itself among general practitioners and infectious disease specialists as an effective and safe preparation for the treatment of most respiratory viral infections, including COVID-19. In 2022, clinical studies of the efficacy and safety of the use of Triazavirin in children aged 12–17 years with a diagnosis of acute respiratory viral infections were successfully completed. Currently, an approval is expected for clinical trials in children of the next age group – from 6 to 11 years.
On the first day of the exhibition, a conference dedicated to the development prospects of the medical and pharmaceutical industry in the Sverdlovsk Region was held as part of the Effective Healthcare Technologies forum. Natalia Musalnikova, Quality Director of Medsintez Plant LLC, delivered a report “On the Development of the Urals Pharmaceutical Industry. Biotechnology – a Confident Step into the Future!” Ms. Musalnikova spoke of successfully implemented biotechnological projects and technological capacities and competences of the Medsintez Plant, which show its great opportunities and prospects. The Plant’s cooperation with scientific institutions, as well as the possibility to develop and produce its own injectable drug delivery devices, opens up horizons for the plant to develop new peptide preparations. In addition, the high-tech facilities of the Medsintez Plant is able to produce any import-substituting medicines based on monoclonal antibodies. The experts attending the conference expressed their deep gratitude to the Medsintez Plant for many years of fruitful work in ensuring the sustainability of drug supply in our country, for the lives of Russian diabetic patients saved during the COVID-19 pandemic, and for the new lives given thanks to the FSH preparation.
The Medsintez Plant has participated in the Healthcare of the Urals exhibition every year since its opening and will continue this good tradition. Therefore, we invite you to visit our booth next year – it always receives a great deal of attention of visitors-specialists and exhibitors. Russian production at the Medsintez Plant ensures a world-class level of quality and safety of manufactured medicines. At that, domestic production of medicines does not depend on exchange-rate fluctuations, which means that it offers favorable prices for finished products in comparison with imported analogues. The plant management sees the prospects for further development in release of new types of medical products and development of new markets. The Plant is ready to launch its own production of reagents for the creation of pharmaceuticals, which will ensure the replacement of inaccessible imported components on the Russian market.
